Rhythm Pharma Drug Lowers BMI in Rare Form of Obesity Rooted in a Dysregulated Brain Pathway

**Phase 3 Trial Shows Imcivree Reduces BMI in Hypothalamic Obesity Patients**

A Phase 3 clinical trial has demonstrated that Rhythm Pharmaceuticals’ drug, Imcivree, successfully achieved body mass index (BMI) reduction targets in patients with hypothalamic obesity. This rare form of obesity arises from dysregulation of the melanocortin-4 receptor (MC4R) pathway in the hypothalamus, a key brain region involved in regulating appetite and energy balance. Imcivree, an engineered peptide therapy, is already approved for treating two other forms of genetically driven obesity.

The trial focused on individuals with hypothalamic obesity, which is typically acquired due to damage or dysfunction in the hypothalamus. The condition disrupts normal metabolic processes and leads to excessive weight gain that is resistant to conventional treatments. By targeting the MC4R pathway, Imcivree aims to restore metabolic regulation. The drug’s prior approvals for genetic obesity conditions highlight its potential as a targeted therapy for disorders linked to this pathway. Further details about the trial outcomes have not yet been disclosed.

Newsflash | Powered by GeneOnline AI

Source: https://medcitynews.com/2025/04/rhythm-pharmaceuticals-hypothalamic-obesity-imcivree-metabolic-setmelanotide-rytm/

Related posts:

Shreyans Bhandari of Bilcare to Appear at PPL Conclave 2025 in Hyderabad on March 7 Generic Drug Stability: Manufacturers Continuously Monitor and Adjust Testing to Meet FDA Guidelines DrugPatentWatch Platform Aids Generic Drug Developers in Expediting Medication Delivery Through Data-Driven Patent Analysis FTO Analyses Essential for Generic Drug Stability Testing to Avoid Patent Infringement.

Author

Mark Chiang